Skin Malignancies Due to Anti-Cancer Therapies

Overview

Journal Cancers (Basel)

Publisher MDPI

Specialty Oncology

Date 2024 Jun 19

PMID 38893081

Authors

Michela Starace

Luca Rapparini

Stephano Cedirian

Affiliations

Soon will be listed here.

Abstract

Skin cancers involve a significant concern in cancer therapy due to their association with various treatment modalities. This comprehensive review explores the increased risk of skin cancers linked to different anti-cancer treatments, including classic immunosuppressants such as methotrexate (MTX), chemotherapeutic agents such as fludarabine and hydroxyurea (HU), targeted therapies like ibrutinib and Janus Kinase inhibitors (JAKi), mitogen-activated protein kinase pathway (MAPKP) inhibitors, sonic hedgehog pathway (SHHP) inhibitors, and radiotherapy. MTX, a widely used immunosuppressant in different fields, is associated with basal cell carcinoma (BCC), cutaneous squamous cell carcinoma (cSCC), and cutaneous melanoma (CM), particularly at higher dosages. Fludarabine, HU, and other chemotherapeutic agents increase the risk of non-melanoma skin cancers (NMSCs), including cSCC and BCC. Targeted therapies like ibrutinib and JAKi have been linked to an elevated incidence of NMSCs and CM. MAPKP inhibitors, particularly BRAF inhibitors like vemurafenib, are associated with the development of cSCCs and second primary melanomas (SPMs). SHHP inhibitors like vismodegib have been linked to the emergence of cSCCs following treatment for BCC. Additionally, radiotherapy carries carcinogenic risks, especially for BCCs, with increased risks, especially with younger age at the moment of exposure. Understanding these risks and implementing appropriate screening is crucial for effectively managing patients undergoing anti-cancer therapies.

References

Kreher M, Noland M, Konda S, Longo M, Valdes-Rodriguez R . Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part I: Calcineurin inhibitors, thiopurines, IMDH inhibitors, mTOR inhibitors, and corticosteroids. J Am Acad Dermatol. 2022; 88(3):521-530. DOI: 10.1016/j.jaad.2022.11.044. View

Moutel M, Noel V, Jary A, Le Q, Lier C, Viguier M . Iatrogenic Kaposi's sarcoma in a myelofibrosis patient treated with ruxolitinib: Case-report, literature review, and French pharmacovigilance data. Am J Hematol. 2021; 97(1):E31-E34. DOI: 10.1002/ajh.26398. View

Kreher M, Konda S, Noland M, Longo M, Valdes-Rodriguez R . Risk of melanoma and nonmelanoma skin cancer with immunosuppressants, part II: Methotrexate, alkylating agents, biologics, and small molecule inhibitors. J Am Acad Dermatol. 2022; 88(3):534-542. DOI: 10.1016/j.jaad.2022.11.043. View

Cohen S, van Vollenhoven R, Winthrop K, Zerbini C, Tanaka Y, Bessette L . Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme. Ann Rheum Dis. 2020; 80(3):304-311. PMC: 7892382. DOI: 10.1136/annrheumdis-2020-218510. View

Peng L, Wang Y, Hong Y, Ye X, Shi P, Zhang J . Incidence and relative risk of cutaneous squamous cell carcinoma with single-agent BRAF inhibitor and dual BRAF/MEK inhibitors in cancer patients: a meta-analysis. Oncotarget. 2017; 8(47):83280-83291. PMC: 5669968. DOI: 10.18632/oncotarget.21059. View

Thoms K, Kuschal C, Emmert S . Lessons learned from DNA repair defective syndromes. Exp Dermatol. 2007; 16(6):532-44. DOI: 10.1111/j.1600-0625.2007.00559.x. View

Lukenbill J, Kalaycio M . Fludarabine: a review of the clear benefits and potential harms. Leuk Res. 2013; 37(9):986-94. DOI: 10.1016/j.leukres.2013.05.004. View

Wetwittayakhlang P, Golovics P, Afif W, Bessissow T, Lakatos P . Tofacitinib-Associated Iatrogenic Kaposi Sarcoma in a Patient With Ulcerative Colitis. ACG Case Rep J. 2021; 8(11):e00678. PMC: 8613348. DOI: 10.14309/crj.0000000000000678. View

Morison W, Momtaz K, Parrish J, Fitzpatrick T . Combined methotrexate-PUVA therapy in the treatment of psoriasis. J Am Acad Dermatol. 1982; 6(1):46-51. DOI: 10.1016/s0190-9622(82)70005-2. View

10.

Radaelli F, Onida F, Rossi F, Zilioli V, Colombi M, Usardi P . Second malignancies in essential thrombocythemia (ET): a retrospective analysis of 331 patients with long-term follow-up from a single institution. Hematology. 2008; 13(4):195-202. DOI: 10.1179/102453308X316022. View

11.

Simeonovski V, Breshkovska H, Duma S, Dohcheva-Karajovanov I, Damevska K, Nikolovska S . Hydroxyurea Associated Cutaneous Lesions: A Case Report. Open Access Maced J Med Sci. 2018; 6(8):1458-1461. PMC: 6108816. DOI: 10.3889/oamjms.2018.320. View

12.

Crow L, Kaizer-Salk K, Juszczak H, Arron S . Medications Associated with Increased Risk of Keratinocyte Carcinoma. Dermatol Clin. 2019; 37(3):297-305. DOI: 10.1016/j.det.2019.02.005. View

13.

March-Rodriguez A, Bellosillo B, Alvarez-Larran A, Besses C, Pujol R, Toll A . Rapidly Growing and Aggressive Cutaneous Squamous Cell Carcinomas in a Patient Treated with Ruxolitinib. Ann Dermatol. 2021; 31(2):204-208. PMC: 7992689. DOI: 10.5021/ad.2019.31.2.204. View

14.

Ron E, Modan B, Preston D, Alfandary E, Stovall M, Boice Jr J . Radiation-induced skin carcinomas of the head and neck. Radiat Res. 1991; 125(3):318-25. View

15.

Keating M, OBrien S, Lerner S, Koller C, Beran M, Robertson L . Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy. Blood. 1998; 92(4):1165-71. View

16.

Flaherty K, Puzanov I, Kim K, Ribas A, McArthur G, Sosman J . Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med. 2010; 363(9):809-19. PMC: 3724529. DOI: 10.1056/NEJMoa1002011. View

17.

Zimmer L, Hillen U, Livingstone E, Lacouture M, Busam K, Carvajal R . Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012; 30(19):2375-83. PMC: 3646308. DOI: 10.1200/JCO.2011.41.1660. View

18.

Polesie S, Gillstedt M, Schmidt S, Egeberg A, Pottegard A, Kristensen K . Use of methotrexate and risk of skin cancer: a nationwide case-control study. Br J Cancer. 2023; 128(7):1311-1319. PMC: 10050200. DOI: 10.1038/s41416-023-02172-7. View

19.

Gavini D, Salvi D, Shah P, Uma D, Lee J, Hamid P . Non-melanoma Skin Cancers in Patients on Hydroxyurea for Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Systematic Review. Cureus. 2021; 13(8):e16978. PMC: 8420994. DOI: 10.7759/cureus.16978. View

20.

Teepen J, Kok J, Kremer L, Tissing W, van den Heuvel-Eibrink M, Loonen J . Long-Term Risk of Skin Cancer Among Childhood Cancer Survivors: A DCOG-LATER Cohort Study. J Natl Cancer Inst. 2019; 111(8):845-853. PMC: 6695299. DOI: 10.1093/jnci/djy212. View